MultiVir to price IPO of 4.6 million shares between $12.00 and $14.00

RBC Capital, Nomura, Cantor Fitzgerald and LifeSci to assist with sale

By Devika Patel

Knoxville, Tenn., April 23 – MultiVir Inc. will sell 4.6 million common shares in its initial public offering with a 30-day greenshoe option of 690,000 additional shares, according to a Form S-1/A filed Friday with the Securities and Exchange Commission. The company has registered up to $74.6 million of stock for the deal, which was announced on March 30.

The shares will be sold at a price expected to fall between $12.00 and $14.00 per share.

RBC Capital Markets, LLC is the bookrunner, Nomura Securities International, Inc. is the lead manager, and Cantor Fitzgerald & Co. and LifeSci Capital LLC are the co-managers.

Proceeds will be used for research and development, clinical trials, bonuses, general and administrative expenses, working capital and other general corporate purposes.

The gene therapy company is based in Houston. The company intends to list its common stock on the Nasdaq under the symbol “MVIR.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.